BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...identified top indications and sorted out manufacturing, Palleon...
...enzymatic sialoglycan degrader to the clinic for cancer.Palleon Pharmaceuticals Inc.’s...
...in cancer and autoimmunity.Through its EAGLE platform, Palleon...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...proximity principles behind PROTACs outside of proteasomal degradation. Another, Palleon Pharmaceuticals Inc., was also co-founded by Bertozzi; Palleon’s...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...June 2019 with a $104 million series C round (see “$104M Series C Debut” ). Palleon Pharmaceuticals Inc....
...to the newly created position of CSO from SVP of research and early product development. Palleon...
...inhibitors of glyco-immune checkpoints found on both adaptive and innate immune cells for cancer (see “Palleon...
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

...said it isn’t sialic acid. Pneumagen is among a growing number of companies -- including Palleon Pharmaceuticals Inc....
...is not based on antibodies (see “Interest in Carbohydrate Antigens Grows with Siamab Acquisition” ; “Palleon...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...Stanford University professor Carolyn Bertozzi. Bertozzi is the scientific founder of Lycia Therapeutics Inc. and Palleon Pharmaceuticals Inc....
...agonize a certain function, but enzymes are a great modality for intervening in biology,” said Palleon...
...The broader targeting strategies are also being developed against non-protein substrates, including glycoproteins and RNA. Palleon's...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...GPS Coordinates"). “This is a broader spectrum checkpoint pathway than the first generation.” Jim Broderick, Palleon...
...SIGLECs are expressed in a very broad way," said Jim Broderick, CEO and founder of Palleon Pharmaceuticals Inc....
..."This is a broader spectrum checkpoint pathway than the first generation." New territory: signaling modulation Palleon’s...
BioCentury | Oct 18, 2019
Targets & Mechanisms

How glycoRNA could go from surprise discovery to therapeutic target

...and systems biology at Stanford University and cofounder of two therapeutics companies targeting protein glycobiology: Palleon Pharmaceuticals Inc....
BioCentury | May 11, 2019
Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

...what other receptors could we hijack for this?" On March 29, a team led by Palleon...
...at Stanford University. The investigators did not return requests for comment in time for publication. Palleon Pharmaceuticals Inc....
...Waltham, Mass.) is developing antibody-enzyme conjugates that degrade immunosuppressive glycans on cell surface receptors (see "Palleon...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

...multidrug-resistant Gram-negative infections (see “Frazier-backed Recida Launches with $8.5M Series A” ). Meanwhile, SR One-backed Palleon Pharmaceuticals Inc....
...glycan ligands and their receptors, is looking ahead to its first IND submissions next year. Palleon...
...detect RSK2 activation in cancer patients (see “Reducing R(I)sk in TNBC” ). BC Staff Heptares Therapeutics Ltd. HiberCell Inc. Palleon Pharmaceuticals Inc. Phoenix...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc....
...tumor surface to trick the immune system to turn off when it should be on,” Palleon...
...Palleon presented the data at the American Association for Cancer Research (AACR) meeting last year. Palleon...
Items per page:
1 - 10 of 12
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...identified top indications and sorted out manufacturing, Palleon...
...enzymatic sialoglycan degrader to the clinic for cancer.Palleon Pharmaceuticals Inc.’s...
...in cancer and autoimmunity.Through its EAGLE platform, Palleon...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...proximity principles behind PROTACs outside of proteasomal degradation. Another, Palleon Pharmaceuticals Inc., was also co-founded by Bertozzi; Palleon’s...
BioCentury | Feb 15, 2020
Management Tracks

Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more

...June 2019 with a $104 million series C round (see “$104M Series C Debut” ). Palleon Pharmaceuticals Inc....
...to the newly created position of CSO from SVP of research and early product development. Palleon...
...inhibitors of glyco-immune checkpoints found on both adaptive and innate immune cells for cancer (see “Palleon...
BioCentury | Feb 13, 2020
Emerging Company Profile

Pneumagen: out-competing viral sugar binding to prevent infection

...said it isn’t sialic acid. Pneumagen is among a growing number of companies -- including Palleon Pharmaceuticals Inc....
...is not based on antibodies (see “Interest in Carbohydrate Antigens Grows with Siamab Acquisition” ; “Palleon...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...Stanford University professor Carolyn Bertozzi. Bertozzi is the scientific founder of Lycia Therapeutics Inc. and Palleon Pharmaceuticals Inc....
...agonize a certain function, but enzymes are a great modality for intervening in biology,” said Palleon...
...The broader targeting strategies are also being developed against non-protein substrates, including glycoproteins and RNA. Palleon's...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...GPS Coordinates"). “This is a broader spectrum checkpoint pathway than the first generation.” Jim Broderick, Palleon...
...SIGLECs are expressed in a very broad way," said Jim Broderick, CEO and founder of Palleon Pharmaceuticals Inc....
..."This is a broader spectrum checkpoint pathway than the first generation." New territory: signaling modulation Palleon’s...
BioCentury | Oct 18, 2019
Targets & Mechanisms

How glycoRNA could go from surprise discovery to therapeutic target

...and systems biology at Stanford University and cofounder of two therapeutics companies targeting protein glycobiology: Palleon Pharmaceuticals Inc....
BioCentury | May 11, 2019
Translation in Brief

Arvinas, Palleon founders extend the reach of targeted degraders

...what other receptors could we hijack for this?" On March 29, a team led by Palleon...
...at Stanford University. The investigators did not return requests for comment in time for publication. Palleon Pharmaceuticals Inc....
...Waltham, Mass.) is developing antibody-enzyme conjugates that degrade immunosuppressive glycans on cell surface receptors (see "Palleon...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

...multidrug-resistant Gram-negative infections (see “Frazier-backed Recida Launches with $8.5M Series A” ). Meanwhile, SR One-backed Palleon Pharmaceuticals Inc....
...glycan ligands and their receptors, is looking ahead to its first IND submissions next year. Palleon...
...detect RSK2 activation in cancer patients (see “Reducing R(I)sk in TNBC” ). BC Staff Heptares Therapeutics Ltd. HiberCell Inc. Palleon Pharmaceuticals Inc. Phoenix...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc....
...tumor surface to trick the immune system to turn off when it should be on,” Palleon...
...Palleon presented the data at the American Association for Cancer Research (AACR) meeting last year. Palleon...
Items per page:
1 - 10 of 12